
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis, and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo. The primary endpoint was change from baseline in lumbar spine BMD. These results suggest abaloparatide can be considered as an effective anabolic treatment option for men with osteoporosis.
Like
Save
Share